[Tai Tsung] Announcement of the Company's Subscription to Private Placement Ordinary Shares of Xiangyi Pharmaceutical Co., Ltd.
NQ Score
0/100
N1 Content Completeness
4
Key facts
- [Tai Tsung] Announcement of the Company's Subscription to Private Placement Ordinary Shares of Xiangyi Pharmaceutical Co., Ltd.
- Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 million private placement ordinary shares for a maximum of NT$240 million. This will result in Tai Tsung holding an 11.79% stake in Xiangyi, accounting for 19.35% of its total assets and 22.74% of equity attributable to the parent company. An accountant has expressed a non-reasonable opinion on the transaction.
- Source: TWSE
- Date: Thu May 07 2026 09:00:00 GMT+0900 (Japan Standard Time)
Direct answer
Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 million private placement ordinary shares for a maximum of NT$240 million. This will result in Tai Tsung holding an 11.79% stake in Xiangyi, accounting for 19.35% of its total assets and 22.74% of equity attributable to the parent company. An accountant has expressed a non-reasonable opinion on the transaction.
- Citation
- [Tai Tsung] Announcement of the Company's Subscription to Private Placement Ordinary Shares of Xiangyi Pharmaceutical Co., Ltd. (Thu May 07 2026 09:00:00 GMT+0900 (Japan Standard Time)), TWSE
- Source
- TWSE
- Date
- Thu May 07 2026 09:00:00 GMT+0900 (Japan Standard Time)
AI Summary (NQ-processed)
Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 million private placement ordinary shares for a maximum of NT$240 million. This will result in Tai Tsung holding an 11.79% stake in Xiangyi, accounting for 19.35% of its total assets and 22.74% of equity attributable to the parent company. An accountant has expressed a non-reasonable opinion on the transaction.
AI Analysis
Frequently Asked Questions
- Q: What are the key facts in this article?
- A: Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 million private placement ordinary shares for a maximum of NT$240 million. This will result in Tai Tsung holding an 11.79% stake in Xiangyi, accounting for 19.35% of its total assets and 22.74% of equity attributable to the parent company. An accountant has expressed a non-reasonable opinion on the transaction.
- Q: What is the direct answer?
- A: Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 million private placement ordinary shares for a maximum of NT$240 million. This will result in Tai Tsung holding an 11.79% stake in Xiangyi, accounting for 19.35% of its total assets and 22.74% of equity attributable to the parent company. An accountant has expressed a non-reasonable opinion on the transaction.
- Q: What is the source and date?
- A: Source: https://mops.twse.com.tw/material/twse-4169-2026-05-07-81fe63c0 | Date: Thu May 07 2026 09:00:00 GMT+0900 (Japan Standard Time)